Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Management of peripheral arterial disease in the elderly: focus on cilostazol Falconer TM; Eikelboom JW; Hankey GJ; Norman PEClin Interv Aging 2008[]; 3 (1): 17-23Symptomatic and asymptomatic peripheral arterial disease (PAD) is a common problem in the elderly. The management of PAD includes the prevention of cardiovascular events and relief of symptoms--most commonly intermittent claudication (IC). Both require treatment of the causes and consequences of atherothrombosis, but some strategies are more effective for prevention of cardiovascular events and others are more effective for the relief of symptoms. Priorities for the prevention of cardiovascular events include smoking cessation, exercise, antiplatelet therapy, and the treatment of dyslipidemia, hypertension, and diabetes. Walking time and ability are improved by exercise. The benefit of numerous drugs in the treatment of IC has been assessed. The results have generally been disappointing, but there is some evidence that statins and cilostazol (an inhibitor of phosphodiesterase 3) are of benefit. Meta-analyses suggest that cilostazol increases maximum walking distance by 40%-50% and improves other objective measures of walking. The safety profile of cilostazol in patients with PAD appears to be acceptable although the mechanism for its effect on IC is unclear. In addition to risk factor management, treatment with cilostazol should be considered in patients with disabling IC.|Aged[MESH]|Cilostazol[MESH]|Diabetic Angiopathies/drug therapy[MESH]|Dose-Response Relationship, Drug[MESH]|Dyslipidemias/epidemiology[MESH]|Humans[MESH]|Hypertension/epidemiology[MESH]|Intermittent Claudication/drug therapy[MESH]|Peripheral Vascular Diseases/*drug therapy/epidemiology[MESH]|Phosphodiesterase Inhibitors/administration & dosage/*therapeutic use[MESH]|Smoking Cessation[MESH]|Smoking/epidemiology[MESH]|Tetrazoles/administration & dosage/*therapeutic use[MESH] |
